Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: Implications for normal aging and age-dependent neurodegenerative disorders

Autophagy

Volumn 8, Issue 1, 2012, Pages 147-151

  Graziotto, John J ^a   Cao, Kan ^b   Collins, Francis S ^c   Krainc, Dimitri ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b University of Maryland   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Aging; Autophagy; Neurodegeneration; Progeria; Progerin; Rapamycin

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BAFILOMYCIN A1; EVEROLIMUS; HUNTINGTIN; LAMIN A; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; POLYUBIQUITIN; PROGERIN; PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P62; RAPAMYCIN; RAS PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOPHAGY; DEGENERATIVE DISEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY GRAFT REJECTION; NONHUMAN; NOTE; PARKINSON DISEASE; PROGERIA; SIDE EFFECT; UBIQUITINATION; WOUND HEALING IMPAIRMENT;

EID: 84856426651     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.8.1.18331     Document Type: Note

References (56)

1. Capell BC, Collins FS. Human laminopathies: nuclei gone genetically awry. Nat Rev Genet 2006; 7:940-52; PMID:17139325; http://dx.doi.org/10.1038/nrg1906
2. Korf B. Hutchinson-Gilford progeria syndrome, aging, and the nuclear lamina. N Engl J Med 2008; 358: 552-5; PMID:18256390; http://dx.doi.org/10.1056/ NEJMp0800071
3. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 2008; 358:592-604; PMID:18256394; http://dx.doi.org/10.1056/NEJMoa0706898
4. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423:293-8; PMID:12714972; http://dx.doi.org/10.1038/nature01629
5. Beck LA, Hosick TJ, Sinensky M. Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol 1990; 110:1489-99; PMID:2335559; http://dx.doi.org/10.1083/jcb.110.5.1489
6. Pendás AM, Zhou Z, Cadinanos J, et al. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. Nat Genet 2002; 31:94-9; PMID:11923874
7. Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M. Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci USA 1992; 89:3000-4; PMID:1557405; http://dx.doi.org/10.1073/pnas.89.7.3000
8. Goldman RD, Shumaker DK, Erdos MR, et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004; 101:8963-8; PMID:15184648; http://dx.doi.org/10.1073/pnas.0402943101
9. Capell BC, Olive M, Erdos MR, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci USA 2008; 105:15902-7; PMID:18838683; http://dx.doi.org/10.1073/pnas.0807840105
10. Bergo MO, Gavino B, Ross J, et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci USA 2002; 99:13049-54; PMID: 12235369; http://dx.doi.org/10. 1073/pnas.192460799
11. Agarwal AK, Fryns JP, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet 2003; 12:1995-2001; PMID:12913070; http://dx.doi.org/10.1093/hmg/ddg213
12. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990; 62:81-8; PMID:2194674; http://dx.doi.org/10.1016/0092-8674(90)90242-7
13. Capell BC, Erdos MR, Madigan JP, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005; 102:12879-84; PMID:16129833; http://dx.doi.org/10.1073/pnas.0506001102
14. Yang SH, Bergo MO, Toth JI, et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA 2005; 102:10291-6; PMID:16014412; http://dx.doi.org/10.1073/pnas.0504641102
15. Fong LG, Frost D, Meta M, et al. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 2006; 311:1621-3; PMID: 16484451; http://dx.doi.org/10.1126/science.1124875
16. Moskalev AA, Shaposhnikov MV. Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. Rejuvenation Res 2010; 13:246-7; PMID:20017609; http://dx.doi.org/10.1089/rej. 2009.0903
17. Bjedov I, Toivonen JM, Kerr F, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010; 11:35-46; PMID:20074526; http://dx.doi.org/10.1016/j.cmet.2009.11.010
18. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66:191-201; PMID:20974732; http://dx.doi.org/10.1093/ gerona/glq178
19. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460:392-5; PMID:19587680
20. Alvers AL, Fishwick LK, Wood MS, et al. Autophagy and amino acid homeostasis are required for chronological longevity in Saccharomyces cerevisiae. Aging Cell 2009; 8:353-69; PMID:19302372; http://dx.doi.org/10.1111/ j.1474-9726.2009.00469.x
21. Hansen M, Chandra A, Mitic LL, Onken B, Driscoll M, Kenyon C. A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet 2008; 4:e24; PMID:18282106; http://dx.doi.org/10.1371/journal.pgen. 0040024
22. Cao K, Graziotto JJ, Blair CD, et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med 2011; 3:89ra58; PMID: 21715679; http://dx.doi.org/10.1126/scitranslmed.3002346
23. Tan JM, Wong ES, Kirkpatrick DS, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 2008; 17:431-9; PMID:17981811; http://dx.doi.org/10.1093/hmg/ddm320
24. Belzile JP, Richard J, Rougeau N, Xiao Y, Cohen EA. HIV-1 Vpr induces the K48-linked polyubiquitination and proteasomal degradation of target cellular proteins to activate ATR and promote G2 arrest. J Virol 2010; 84:3320-30; PMID:20089662; http://dx.doi.org/10.1128/JVI.02590-09
25. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009; 10:659-71; PMID:19773779; http://dx.doi.org/10.1038/nrm2767
26. Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 2007; 131:1149-63; PMID:18083104; http://dx.doi.org/10.1016/j.cell.2007.10.035
27. Jeong H, Then F, Melia TJ, Jr., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009; 137:60-72; PMID:19345187; http://dx.doi.org/10.1016/j.cell.2009.03.018
28. Filimonenko M, Isakson P, Finley KD, et al. The selective macroautophagic degradation of aggregated proteins requires the PI3P-binding protein Alfy. Mol Cell 2010; 38:265-79; PMID:20417604; http://dx.doi.org/10.1016/j.molcel.2010.04. 007
29. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008; 198:39-48; PMID:17980369; http://dx.doi.org/10.1016/j.atherosclerosis.2007.09.019
30. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3:562-9; PMID:12752312; http://dx.doi.org/10.1034/j. 1600-6143.2003.00094.x
31. Waksman R, Pakala R, Burnett MS, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003; 4:34-8; PMID:12892771; http://dx.doi.org/10.1016/S1522-1865(03)00121-5
32. Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002; 11:1107-17; PMID:11978769; http://dx.doi.org/10.1093/hmg/11.9.1107
33. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36:585-95; PMID:15146184; http://dx.doi.org/10.1038/ng1362
34. Rose C, Menzies FM, Renna M, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 2010; 19:2144-53; PMID:20190273; http://dx.doi.org/10.1093/hmg/ddq093
35. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443:780-6; PMID:17051204; http://dx.doi.org/10.1038/nature05291
36. Zemke D, Azhar S, Majid A. The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect 2007; 20:495-9; PMID:18080036; http://dx.doi.org/10.1358/dnp.2007.20.8.1157618
37. Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007; 3:331-8; PMID:17486044; http://dx.doi.org/10.1038/nchembio883
38. Berger Z, Ravikumar B, Menzies FM, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 2006; 15:433-42; PMID:16368705; http://dx.doi.org/10.1093/hmg/ddi458
39. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 2009; 164:541-51; PMID:19682553; http://dx.doi.org/10.1016/j.neuroscience.2009.08.014
40. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146:37-52; PMID:21700325; http://dx.doi.org/10.1016/j.cell.2011.06.001
41. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282:5641-52; PMID:17182613; http://dx.doi.org/10.1074/jbc.M609532200
42. Crews L, Spencer B, Desplats P, et al. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS ONE 2010; 5:e9313; PMID:20174468; http://dx.doi.org/10.1371/journal.pone.0009313
43. Dehay B, Bove J, Rodriguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci 2010; 30:12535-44; PMID:20844148; http://dx.doi.org/10.1523/JNEUROSCI.1920-10.2010
44. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010; 285:13107-20; PMID:20178983; http://dx.doi.org/10.1074/jbc.M110.100420
45. Spilman P, Podlutskaya N, Hart MJ, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010; 5:e9979; PMID:20376313; http://dx.doi.org/10.1371/journal.pone.0009979
46. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science 2006; 312:1059-63; PMID:16645051; http://dx.doi.org/10.1126/science. 1127168
47. McClintock D, Ratner D, Lokuge M, et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2007; 2:e1269; PMID: 18060063; http://dx.doi.org/10.1371/journal. pone.0001269
48. Olive M, Harten I, Mitchell R, et al. Cardiovascular pathology in hutchinson-gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010; 30:2301-9; PMID:20798379; http://dx.doi.org/10.1161/ATVBAHA.110.209460
49. Scaffidi P, Misteli T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 2008; 10:452-9; PMID: 18311132; http://dx.doi.org/10.1038/ncb1708
50. Cao K, Blair CD, Faddah DA, et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J Clin Invest 2011; 121:2833-44; PMID:21670498; http://dx.doi.org/10.1172/JCI43578
51. Benson EK, Lee SW, Aaronson SA. Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence. J Cell Sci 2010; 123:2605-12; PMID:20605919; http://dx.doi.org/10.1242/jcs.067306
52. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25:2004-10; PMID:20106825; http://dx.doi.org/10.1093/ndt/gfp778
53. Baur B, Oroszlan M, Hess O, Carrel T, Mohacsi P. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplant Proc 2011; 43:1853-61; PMID:21693289; http://dx.doi.org/10.1016/j. transproceed.2011.01.174
54. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006; 38:711-3; PMID:16647451; http://dx.doi.org/10.1016/j.transproceed.2006.01.052
55. González D, Garcia CD, Azocar M, et al. Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 2011; 26:961-6; PMID: 21380626; http://dx.doi.org/10.1007/s00467-011-1811-3
56. Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005; 170:1101-11; PMID:16186256; http://dx.doi.org/10.1083/jcb.200504035